Kathy D. Miller, MD
Phone: (317) 944-0920
Phone: (317) 944-0920, Patient issues/appointments
980 W. Walnut Street
R3 Room C218E
Indianapolis, IN 46202
Faculty appointments
- Ballvé Lantero Professor of Oncology, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
- Professor of Medicine, Department of Medicine, IU School of Medicine
- Associate Director of Clinical Research, IU Simon Comprehensive Cancer Center
- Full member
, Experimental and Developmental Therapeutics
Headlines & highlights
- Chemotherapy type can be personalized to decrease harmful side effects for Black patients with breast cancer (June 2024)
- Susan G. Komen® welcomes nine leaders to research advisory roles (Apr. 2023)
- Genomic medicine key to treating aggressive breast cancers disproportionately affecting African American women (Oct. 2021)
- Cancer center researchers part of a collaborative $12.4 million SPORE grant from National Cancer Institute (Sept. 2021)
- Cancer center experts offer insight for staying healthy during the pandemic (Nov. 2020)
- Genomic medicine key to treating aggressive breast cancers disproportionately affecting African American women (Oct. 2020)
- Why does Kathy Miller hate pink? (Jan. 2020)
- IU Simon Cancer Center 2018 Scientific Report (Jan. 2019)
- Kathy Miller, MD, discusses clinical trials at IU (June 2018)
Biography
Kathy D. Miller, MD, was appointed associate director of clinical research in October 2017. She received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore. Dr. Miller completed internal medicine training at Hopkins, then returned to her native Midwest for fellowship training at Indiana University, serving as chief fellow in 1997. She returned to Indiana University in 1999, attaining the rank of professor and Ballvé-Lantero Scholar in 2014.
Dr. Miller’s career has combined both laboratory and clinical research in breast cancer. She was chair of the ECOG-ACRIN Breast Core Committee in January 2014 through December 2017. In this role, she worked with academic scientists and community oncologists to develop trials that combined clinical and biologic endpoints yet remained feasible in non-academic settings. Dr. Miller honed her ability to coordinate multi-center trials as principal investigator for three previous ECOG trials. Dr. Miller was elected co-chair of the National Cancer Institute Breast Cancer Steering Committee in late 2017, serving two three-year terms.
